Pancragen
Also known as: Peptídeo pancreático
Molecular Identifiers
Overview
Pancreatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in pancreatic cells and supports beta cell function. Used in short cycles for pancreatic function protection and support.
KEDW Lys-Glu-Asp-Trp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in pancreatic cells
- Support for beta cell function and viability
- Normalization of insulin secretion
- Modulation of pancreatic glycemic metabolism
- Bioregulatory effect on endocrine and exocrine pancreas
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous injection |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Very stable tetrapeptide. Protect from light and moisture. |
Presentations & Preparation
Vials of Pancragen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Pancragen.
Effects of pancragen on the differentiation of pancreatic cells during their ageing
Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV, Tarnovskaya SI
Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys
Goncharova ND, Ivanova LG, Oganyan TE, Vengerin AA, Khavinson VKh
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily